SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 18 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Bizumentary to Premiere Sept. 24 Across National Networks
Beeline Holdings (NASDAQ: BLNE) announced that its “Bizumentary,” produced in partnership with Emmy Award-winning Loft…
-
QualityStocksNewsBreaks – Nocera, Inc. (NASDAQ: NCRA) Enters Worldwide Joint Distribution Agreement With E-PRO
Nocera (NASDAQ: NCRA) entered into a Strategic Partnership and Joint Distribution Agreement with Taiwan-based E-PRO…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Appoints Brian Goldenberg as Chief Financial Officer
Versus Systems (NASDAQ: VS) announced the appointment of Brian Goldenberg, CPA, as Chief Financial Officer,…